Basic Stats
| CIK | 880771 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to SciClone Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| February 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SCICLONE PHARMACEUTICALS INC (Name of Issuer) Common Stock (Title of Class of Securities) 80862K104 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| October 31, 2017 |
SciClone Pharmaceuticals S-8 POS S-8 POS 1 d485072ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. 333-12169 Registration No. 333-62059 Registration No. 333-45820 Registration No. 333-98081 Registration No. 333-109256 Registration No. 333-120008 Registration No. 333-128482 Registration No. 333-145281 Registration No. 333-168668 Registration No. 333-183171 Registration No |
|
| October 31, 2017 |
SciClone Pharmaceuticals S-8 POS S-8 POS 1 d485072ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. 333-12169 Registration No. 333-62059 Registration No. 333-45820 Registration No. 333-98081 Registration No. 333-109256 Registration No. 333-120008 Registration No. 333-128482 Registration No. 333-145281 Registration No. 333-168668 Registration No. 333-183171 Registration No |
|
| October 31, 2017 |
SciClone Pharmaceuticals S-8 POS S-8 POS 1 d485072ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. 333-12169 Registration No. 333-62059 Registration No. 333-45820 Registration No. 333-98081 Registration No. 333-109256 Registration No. 333-120008 Registration No. 333-128482 Registration No. 333-145281 Registration No. 333-168668 Registration No. 333-183171 Registration No |
|
| October 31, 2017 |
SciClone Pharmaceuticals S-8 POS S-8 POS 1 d485072ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. 333-12169 Registration No. 333-62059 Registration No. 333-45820 Registration No. 333-98081 Registration No. 333-109256 Registration No. 333-120008 Registration No. 333-128482 Registration No. 333-145281 Registration No. 333-168668 Registration No. 333-183171 Registration No |
|
| October 31, 2017 |
SciClone Pharmaceuticals S-8 POS S-8 POS 1 d485072ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. 333-12169 Registration No. 333-62059 Registration No. 333-45820 Registration No. 333-98081 Registration No. 333-109256 Registration No. 333-120008 Registration No. 333-128482 Registration No. 333-145281 Registration No. 333-168668 Registration No. 333-183171 Registration No |
|
| October 31, 2017 |
SciClone Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. |
|
| October 31, 2017 |
SciClone Pharmaceuticals S-8 POS S-8 POS 1 d485072ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. 333-12169 Registration No. 333-62059 Registration No. 333-45820 Registration No. 333-98081 Registration No. 333-109256 Registration No. 333-120008 Registration No. 333-128482 Registration No. 333-145281 Registration No. 333-168668 Registration No. 333-183171 Registration No |
|
| October 31, 2017 |
SciClone Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. |
|
| October 31, 2017 |
SciClone Pharmaceuticals S-8 POS S-8 POS 1 d485072ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. 333-12169 Registration No. 333-62059 Registration No. 333-45820 Registration No. 333-98081 Registration No. 333-109256 Registration No. 333-120008 Registration No. 333-128482 Registration No. 333-145281 Registration No. 333-168668 Registration No. 333-183171 Registration No |
|
| October 31, 2017 |
SciClone Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. |
|
| October 31, 2017 |
SciClone Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. |
|
| October 31, 2017 |
SciClone Pharmaceuticals S-8 POS S-8 POS 1 d485072ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. 333-12169 Registration No. 333-62059 Registration No. 333-45820 Registration No. 333-98081 Registration No. 333-109256 Registration No. 333-120008 Registration No. 333-128482 Registration No. 333-145281 Registration No. 333-168668 Registration No. 333-183171 Registration No |
|
| October 31, 2017 |
SciClone Pharmaceuticals POS AM POS AM 1 d486116dposam.htm POS AM As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. 333-52471 Registration No. 333-62309 Registration No. 333-77543 Registration No. 333-81481 Registration No. 333-84487 Registration No. 333-85673 Registration No. 333-30938 Registration No. 333-72800 Registration No. 333-176209 Registration No. 333-216565 UNITED STATES SECURIT |
|
| October 31, 2017 |
SciClone Pharmaceuticals POS AM POS AM As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. |
|
| October 31, 2017 |
SciClone Pharmaceuticals POS AM As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. |
|
| October 31, 2017 |
SciClone Pharmaceuticals POS AM As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. |
|
| October 31, 2017 |
SciClone Pharmaceuticals POS AM As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. |
|
| October 31, 2017 |
SciClone Pharmaceuticals POS AM As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. |
|
| October 31, 2017 |
SciClone Pharmaceuticals POS AM As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. |
|
| October 31, 2017 |
SciClone Pharmaceuticals POS AM As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. |
|
| October 31, 2017 |
SciClone Pharmaceuticals POS AM As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. |
|
| October 31, 2017 |
SciClone Pharmaceuticals POS AM As filed with the Securities and Exchange Commission on October 31, 2017 Registration No. |
|
| October 25, 2017 |
SciClone Pharmaceuticals 15-12G 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 0-19825 SciClone Pharmaceuticals, Inc. (Exact name of registrant as s |
|
| October 17, 2017 |
SC 13D/A 1 p17-2081sc13da.htm SCICLONE PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* SciClone Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 80862K104 (CUSIP Number) Man Group plc Riverbank House 2 Swan Lane London EC4R 3AD Un |
|
| October 16, 2017 |
Amendment No. 1 to ROLLOVER AGREEMENT EX-15 2 tv477011ex15.htm EXHIBIT 15 Exhibit 15 Amendment No. 1 to ROLLOVER AGREEMENT This Amendment No. 1 (this “Amendment”) to that certain ROLLOVER AGREEMENT, dated as of June 7, 2017 (the “Agreement”), is made and entered into as of October 13, 2017, by and among Silver Biotech Elements Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (“Eleme |
|
| October 16, 2017 |
SC 13D/A 1 tv477011sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value US$0.001 per sh |
|
| October 13, 2017 |
Amended and Restated Certificate of Incorporation of SciClone Pharmaceuticals, Inc. EX-3.1 EXHIBIT 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SCICLONE PHARMACEUTICALS, INC. FIRST: The name of the Corporation is SciClone Pharmaceuticals, Inc. (hereinafter the ?Corporation?). SECOND: The address of the registered office of the Corporation in the State of Delaware is 251 Little Falls Drive, Wilmington, County of New Castle, 19808. The name of its registered agent at th |
|
| October 13, 2017 |
Amended and Restated Bylaws of SciClone Pharmaceuticals, Inc. EX-3.2 Table of Contents EXHIBIT 3.2 AMENDED AND RESTATED BY-LAWS OF SCICLONE PHARMACEUTICALS, INC. A Delaware Corporation Effective October 13, 2017 Table of Contents TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1.1 Registered Office 1 Section 1.2 Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 2 Section 2.1 Place of Meetings 2 Section 2.2 Annual Meetings 2 Section 2.3 Special Meetings |
|
| October 13, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: October 13, 2017 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdiction of incorporat |
|
| September 27, 2017 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: September 27, 2017 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdiction of incorporation) (C |
|
| September 15, 2017 |
SciClone Pharmaceuticals DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Rule 14a-101) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| August 18, 2017 |
SciClone Pharmaceuticals DEFINITIVE PROXY STATEMENT PERTAINING TO A MERGER DEFM14A 1 d391632ddefm14a.htm DEFINITIVE PROXY STATEMENT PERTAINING TO A MERGER Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Rule 14a-101) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Sta |
|
| August 10, 2017 |
SCICLONE ANNOUNCES END OF GO-SHOP PERIOD WITH NO PARTIES DESIGNATED AS EXCLUDED PARTIES EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE ANNOUNCES END OF GO-SHOP PERIOD WITH NO PARTIES DESIGNATED AS EXCLUDED PARTIES FOSTER CITY, CA, August 10, 2017 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) (the Company or SciClone) today announced the expira |
|
| August 10, 2017 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 10, 2017 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-19825 (Commis |
|
| August 10, 2017 |
SCICLONE ANNOUNCES END OF GO-SHOP PERIOD WITH NO PARTIES DESIGNATED AS EXCLUDED PARTIES EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE ANNOUNCES END OF GO-SHOP PERIOD WITH NO PARTIES DESIGNATED AS EXCLUDED PARTIES FOSTER CITY, CA, August 10, 2017 SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) (the Company or SciClone) today announced the expira |
|
| August 10, 2017 |
SciClone Pharmaceuticals FORM 8-K DEFA14A 1 d438802d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 10, 2017 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incor |
|
| August 10, 2017 |
SciClone Pharmaceuticals DEFA14A DEFA14A 1 d436459ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| August 9, 2017 |
SCICLONE REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS Exhibit 991 Q217 Financial Results Exhibit 99.1 ? Corporate Contacts ? ? Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] ? SCICLONE REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS ? ? FOSTER CITY, CA ? August 9, 2017 ? SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter |
|
| August 9, 2017 |
SciClone Pharmaceuticals 8-K (Current Report/Significant Event) 2017 Q217 Form 8-K Financial Results UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 9, 2017 |
SCLN / SciClone Pharmaceuticals, Inc. 10-Q (Quarterly Report) 10-Q 1 scln-20170630x10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the |
|
| August 2, 2017 |
SciClone Pharmaceuticals PRELIMINARY PROXY STATEMENT PERTAINING TO A MERGER Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Rule 14a-101) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| July 27, 2017 |
SC 13D 1 p17-1581sc13d.htm SCICLONE PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. [])* SciClone Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 80862K104 (CUSIP Number) Man Group plc Riverbank House 2 Swan Lane London EC4R 3AD United |
|
| June 23, 2017 |
8-K 1 d407398d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: June 22, 2017 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdiction |
|
| June 23, 2017 |
DEFA14A 1 d407398d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: June 22, 2017 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdict |
|
| June 9, 2017 |
SciClone Pharmaceuticals DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| June 9, 2017 |
SciClone Pharmaceuticals DEFA14A DEFA14A 1 d380999ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| June 9, 2017 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: June 8, 2017 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdiction of incorporation) |
|
| June 8, 2017 |
SciClone Pharmaceuticals DEFA14A DEFA14A 1 d326536ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| June 8, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: June 7, 2017 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdiction of incorporation) (Com |
|
| June 8, 2017 |
EX-10.1 Exhibit 10.1 Execution Version Voting and Support Agreement VOTING AND SUPPORT AGREEMENT, dated as of June 7, 2017 (this Agreement), by and between GL Trade Investment Limited, a company incorporated under the laws of the Cayman Islands (the Stockholder), and SciClone Pharmaceuticals, Inc., a Delaware corporation (the Company). Capitalized terms used and not otherwise defined herein |
|
| June 8, 2017 |
EX-2.1 Table of Contents Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among SCICLONE PHARMACEUTICALS, INC., SILVER BIOTECH INVESTMENT LIMITED, and SILVER DELAWARE INVESTMENT LIMITED Dated June 7, 2017 Table of Contents TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 Section 1.1 Definitions 2 ARTICLE II THE MERGER; CLOSING; EFFECTIVE TIME 13 Section 2.1 The Merger 13 Section 2.2 |
|
| June 8, 2017 |
EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE ENTERS INTO DEFINITIVE MERGER AGREEMENT TO BE ACQUIRED BY CONSORTIUM LED BY GL CAPITAL SciClone to be acquired for $11.18 per share, representing a valuation of approximately $605 million FOSTER CITY, CA, June 8, 201 |
|
| June 8, 2017 |
EX-2.1 Table of Contents Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among SCICLONE PHARMACEUTICALS, INC., SILVER BIOTECH INVESTMENT LIMITED, and SILVER DELAWARE INVESTMENT LIMITED Dated June 7, 2017 Table of Contents TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 Section 1.1 Definitions 2 ARTICLE II THE MERGER; CLOSING; EFFECTIVE TIME 13 Section 2.1 The Merger 13 Section 2.2 |
|
| June 8, 2017 |
EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE ENTERS INTO DEFINITIVE MERGER AGREEMENT TO BE ACQUIRED BY CONSORTIUM LED BY GL CAPITAL SciClone to be acquired for $11.18 per share, representing a valuation of approximately $605 million FOSTER CITY, CA, June 8, 201 |
|
| June 8, 2017 |
EX-10.1 Exhibit 10.1 Execution Version Voting and Support Agreement VOTING AND SUPPORT AGREEMENT, dated as of June 7, 2017 (this ?Agreement?), by and between GL Trade Investment Limited, a company incorporated under the laws of the Cayman Islands (the ?Stockholder?), and SciClone Pharmaceuticals, Inc., a Delaware corporation (the ?Company?). Capitalized terms used and not otherwise defined herein |
|
| June 8, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: June 7, 2017 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdiction of incorporation) (Com |
|
| June 8, 2017 |
Exhibit 99.8 Execution Version EQUITY COMMITMENT LETTER June 7, 2017 Silver Biotech Investment Limited c/o Unit 3001, China World Tower 2 No. 1 Jian Guo Men Wai Avenue Beijing 100004, People’s Republic of China Attn: Ms. Shirley Lin Re: Equity Commitment Letter Ladies and Gentlemen: This letter sets forth the commitment of the undersigned (the “Sponsor”), subject to (i) the terms and conditions co |
|
| June 8, 2017 |
Exhibit 99.11 Execution Version ROLLOVER AGREEMENT This ROLLOVER AGREEMENT (this “Agreement”) dated as of June 7, 2017 among Silver Biotech Holding Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (“Topco”), Silver Biotech Investment Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (“Holdco”) |
|
| June 8, 2017 |
Exhibit 99.7 Execution Version EQUITY COMMITMENT LETTER June 7, 2017 Silver Biotech Investment Limited c/o Unit 3001, China World Tower 2 No. 1 Jian Guo Men Wai Avenue Beijing 100004, People’s Republic of China Attn: Ms. Shirley Lin Re: Equity Commitment Letter Ladies and Gentlemen: This letter sets forth the commitment of the undersigned (the “Sponsor”), subject to (i) the terms and conditions co |
|
| June 8, 2017 |
CHINA MINSHENG BANKING CORP., LTD. No.2,Fuxingmennei Ave., Xicheng District Beijing 10031 P.R. China Exhibit 99.5 CHINA MINSHENG BANKING CORP., LTD. No.2,Fuxingmennei Ave., Xicheng District Beijing 10031 P.R. China CONFIDENTIAL May 29, 2017 Silver Biotech Investment Limited c/o Unit 3001, China World Tower 2 No. 1 Jian Guo Men Wai Avenue Beijing 100004, People’s Republic of China Attn: Ms. Shirley Lin SciClone Pharmaceuticals, Inc. Commitment Letter Ladies and Gentlemen: You have advised China Mi |
|
| June 8, 2017 |
SC 13D/A 1 v468596sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value US$0.001 per sha |
|
| June 8, 2017 |
Exhibit 99.12 EXECUTION VERSION AMENDED AND RESTATED CONSORTIUM AGREEMENT GL Capital Management GP Limited Bank of China Group Investment Limited Avengers Limited Boying Investments Limited and Ascendent Silver (Cayman) Limited Dated as of June 7, 2017 TABLE OF CONTENTS Page Article I PARTICIPATION IN Transaction; ADVISORS 1 Section 1.01 Participation in the Transaction 1 Section 1.02 Information |
|
| June 8, 2017 |
Exhibit 99.10 Execution Version EQUITY COMMITMENT LETTER June 7, 2017 Silver Biotech Investment Limited c/o Unit 3001, China World Tower 2 No. 1 Jian Guo Men Wai Avenue Beijing 100004, People’s Republic of China Attn: Ms. Shirley Lin Re: Equity Commitment Letter Ladies and Gentlemen: This letter sets forth the commitment of the undersigned (the “Sponsor”), subject to (i) the terms and conditions c |
|
| June 8, 2017 |
Exhibit 99.9 Execution Version EQUITY COMMITMENT LETTER June 7, 2017 Silver Biotech Investment Limited c/o Unit 3001, China World Tower 2 No. 1 Jian Guo Men Wai Avenue Beijing 100004, People’s Republic of China Attn: Ms. Shirley Lin Re: Equity Commitment Letter Ladies and Gentlemen: This letter sets forth the commitment of the undersigned (the “Sponsor”), subject to (i) the terms and conditions co |
|
| June 8, 2017 |
Exhibit 99.6 Execution Version EQUITY COMMITMENT LETTER June 7, 2017 Silver Biotech Investment Limited c/o Unit 3001, China World Tower 2 No. 1 Jian Guo Men Wai Avenue Beijing 100004, People’s Republic of China Attn: Ms. Shirley Lin Re: Equity Commitment Letter Ladies and Gentlemen: This letter sets forth the commitment of the undersigned (the “Sponsor”), subject to (i) the terms and conditions co |
|
| June 8, 2017 |
Exhibit 99.14 EXECUTION VERSION ESCROW AGREEMENT This ESCROW AGREEMENT, dated as of June 7, 2017 (together with Schedule A hereto, this “Agreement”), is by and among Silver Biotech Investment Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (“Holdco”); SciClone Pharmaceuticals, Inc., a Delaware corporation (the “Company”); and Computershare Trus |
|
| May 12, 2017 |
CORRESP 1 filename1.htm VIA EDGAR May 12, 2017 Re: SciClone Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-216565) SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dorrie Yale Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on May 11, 2017, in which we requested t |
|
| May 12, 2017 |
CORRESP 1 filename1.htm VIA EDGAR May 12, 2017 Re: SciClone Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-216565) SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dorrie Yale Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, SciClone Pharmaceuticals, Inc. hereby re |
|
| May 11, 2017 |
CORRESP 1 filename1.htm VIA EDGAR May 11, 2017 Re: SciClone Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-216565) SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dorrie Yale Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, SciClone Pharmaceuticals, Inc. hereby re |
|
| May 10, 2017 |
SciClone Pharmaceuticals 10-Q (Quarterly Report) 2017033110Q Q1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 10, 2017 |
SCICLONE REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS Strong ZADAXIN® Growth Continues in 2017 EX-99.1 2 scln-20170510xex991.htm EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS Strong ZADAXIN® Growth Continues in 2017 FOSTER CITY, CA – May 10, 2017 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) to |
|
| May 10, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 scln-20170510x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 10, 2017 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of inco |
|
| May 10, 2017 |
SciClone Pharmaceuticals AMENDMENT NO. 1 TO FORM S-3 S-3/A 1 d256438ds3a.htm AMENDMENT NO. 1 TO FORM S-3 As filed with the Securities and Exchange Commission on May 10, 2017 Registration No. 333-216565 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SCICLONE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware |
|
| May 10, 2017 |
EX-10.1 2 scln-20170331xex101.htm EX-10.1 Exhibit 10.1 SCICLONE PHARMACEUTICALS, INC. NOTICE OF GRANT OF PERFORMANCE-BASED RESTRICTED STOCK UNITS (For US Participant) The Participant has been granted an award (the “Award”) of Performance-Based Restricted Stock Units (each, a “Unit”) pursuant to the SciClone Pharmaceuticals, Inc. 2015 Equity Incentive Plan (the “Plan”) and the attached Performance- |
|
| May 10, 2017 |
Exhibit 10.2 SCICLONE PHARMACEUTICALS, INC. NOTICE OF GRANT OF PERFORMANCE-BASED RESTRICTED STOCK UNITS (For US Participant) The Participant has been granted an award (the “Award”) of Performance-Based Restricted Stock Units (each, a “Unit”) pursuant to the SciClone Pharmaceuticals, Inc. 2015 Equity Incentive Plan (the “Plan”) and the attached Performance-Based Restricted Stock Units Agreement (th |
|
| May 10, 2017 |
EX-10.3 4 scln-20170331xex103.htm EX-10.3 Exhibit 10.3 SCICLONE PHARMACEUTICALS, INC. NOTICE OF GRANT OF PERFORMANCE-BASED RESTRICTED STOCK UNITS (For Residents of the People’s Republic of China) The Participant has been granted an award (the “Award”) of Performance-Based Restricted Stock Units (each, a “Unit”) pursuant to the SciClone Pharmaceuticals, Inc. 2015 Equity Incentive Plan (the “Plan”) |
|
| May 9, 2017 |
AMENDED AND RESTATED BYLAWS SCICLONE PHARMACEUTICALS, INC. ARTICLE I EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF SCICLONE PHARMACEUTICALS, INC. ARTICLE I STOCKHOLDERS SECTION 1.1 Place of Meetings. All meetings of stockholders shall be held at such place within or outside of the State of Delaware as may be designated from time to time by the Board of Directors of the corporation (the ?Board? or the ?Board of Directors?) or the President and Chief Executive Of |
|
| May 9, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 4, 2017 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-19825 (Commission File |
|
| April 28, 2017 |
SciClone Pharmaceuticals DEFA14A DEFA14A 1 c465063defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 28, 2017 |
SciClone Pharmaceuticals DEFINITIVE PROXY STATEMENT DEF 14A 1 c464959def14a.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as |
|
| March 9, 2017 |
EX-4.1 Exhibit 4.1 SCICLONE PHARMACEUTICALS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 3 Section 2.1 Designation and Terms of Securities 3 Section 2.2 Form of Securities and Trustee?s C |
|
| March 9, 2017 |
EX-12.1 Exhibit 12.1 SCICLONE PHARMACEUTICALS, INC. STATEMENT OF COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (in thousands of dollars, except for ratios) Year Ended December 31, 2016 2015 2014 2013 2012 Earnings: Income before taxes $ 34,133 $ 30,270 $ 26,377 $ 13,206 $ 6,272 Add: Combined fixed charges 699 699 797 1,074 1,147 Less: Capitalized interest ? ? ? ? ? Earnings as defined $ 34,832 |
|
| March 9, 2017 |
SciClone Pharmaceuticals FORM S-3 Form S-3 Table of Contents As filed with the Securities and Exchange Commission on March 9, 2017 Registration No. |
|
| March 9, 2017 |
EX-4.2 Exhibit 4.2 SCICLONE PHARMACEUTICALS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 3 Section 2.01 Designation and Terms of Securities 3 Section 2.02 Form of Securities and Tru |
|
| March 9, 2017 |
SciClone Pharmaceuticals 10-K (Annual Report) 20161231 10K FY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 ? Or ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to . Commission file number 0-19825 ? |
|
| March 9, 2017 |
Exhibit 10.43 Friedhelm Blobel, Ph.D. President and CEO (650) 358-3456 CONFIDENTIAL September 30, 2016 Mr. Carey Chern 950 Tower Lane, Suite 900 Foster City, CA 94404 Dear Carey, I am pleased to offer you a position with SciClone Pharmaceuticals, Inc. (the “Company”) as its General Counsel reporting to me, President and Chief Executive Officer of SciClone Pharmaceuticals, Inc. The position |
|
| March 9, 2017 |
EXHIBIT 21.1 SUBSIDIARIES OF REGISTRANT NOVAMED PHARMACEUTICALS INC. NOVAMED PHARMACEUTICALS (SHANGHAI) CO. LTD. SCICLONE PHARMACEUTICALS (CHINA) CO. LTD. SCICLONE PHARMACEUTICALS (CHINA) LTD SCICLONE PHARMACEUTICALS (HONG KONG) DEVELOPMENT COMPANY LTD. SCICLONE PHARMACEUTICALS HONG KONG LIMITED SCICLONE PHARMACEUTICALS INTERNATIONAL (CAYMAN) DEVELOPMENT LIMITED SCICLONE PHARMACEUTICALS IN |
|
| March 9, 2017 |
SCICLONE PHARMACEUTICALS, INC. EMPLOYEE RETENTION AGREEMENT Exhibit 10.42 SCICLONE PHARMACEUTICALS, INC. EMPLOYEE RETENTION AGREEMENT This Employee Retention Agreement (the “Agreement”) is effective as of the October 24, 2016 by and between Name (“Employee”) and SciClone Pharmaceuticals, Inc., a Delaware corporation (the “Company”). For all purposes under this Agreement, the term “Company” shall include any successor to the Company’s business and/or assets |
|
| March 6, 2017 |
Exhibit 991 Q416 Financial Results Exhibit 99.1 ? Corporate Contacts ? ? Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] ? SCICLONE REPORTS 2016 FINANCIAL RESULTS AND 2017 OUTLOOK ? ZADAXIN? Continues Strong Volume Growth; Remains Leading Brand in Thymalfasin Market ? FOSTER CITY, CA ? March 6, 2017 ? SciClone |
|
| March 6, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 2016 Q416 Form 8-K Financial Results UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 3, 2017 |
SciClone Pharmaceuticals 10-Q/A (Quarterly Report) 2016063010QA Q2 ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 3, 2017 |
Manufacturing Services Agreement (the “Agreement”) EX-10.1 2 scln-20160630xex101.htm EX-10.1 Exhibit 10.1 *** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Manufacturing Services Agreement (the “Agreement”) by and between Lonza Sales Ltd Münchens |
|
| March 3, 2017 |
AMENDMENT NO. 3 TO MANUFACTURING SERVICES AGREEMENT EX-10.4 5 scln-20160630xex104.htm EX-10.4 Exhibit 10.4 *** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 3 TO MANUFACTURING SERVICES AGREEMENT THIS AMENDMENT NO. 3 TO MANUFACTURING SE |
|
| March 3, 2017 |
AMENDMENT NO. 4 MANUFACTURING SERVICES AGREEMENT Exhibit 10.5 *** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 4 TO MANUFACTURING SERVICES AGREEMENT THIS AMENDMENT NO. 4 TO MANUFACTURING SERVICES AGREEMENT (this “Amendment No. 4” |
|
| March 3, 2017 |
AMENDMENT NO. 1 TO MANUFACTURING SERVICES AGREEMENT Exhibit 10.2 *** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 1 TO MANUFACTURING SERVICES AGREEMENT THIS AMENDMENT NO. 1 TO MANUFACTURING SERVICES AGREEMENT (this “Amendment No. 1”) |
|
| March 3, 2017 |
Exhibit 10.3 *** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 2 TO the Manufacturing Services Agreement (the “Agreement”) effective April 30, 2014 between Lonza Sales Ltd a |
|
| February 28, 2017 |
AMENDED AND RESTATED BYLAWS SCICLONE PHARMACEUTICALS, INC. ARTICLE I Exhibit 32 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF SCICLONE PHARMACEUTICALS, INC. ARTICLE I STOCKHOLDERS SECTION 1.1 Place of Meetings. All meetings of stockholders shall be held at such place within or without the State of Delaware as may be designated from time to time by the Board of Directors of the corporation (the ?Board? or the ?Board of Directors?) or the President and Chief Executive O |
|
| February 28, 2017 |
8K Certificate of Elimination and Proxy Access Bylaws UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 28, 2017 |
CERTIFICATE OF ELIMINATION SERIES D PREFERRED STOCK OF SCICLONE PHARMACEUTICALS, INC. EX-3.1 2 scln-20170228xex31.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF ELIMINATION OF SERIES D PREFERRED STOCK OF SCICLONE PHARMACEUTICALS, INC. (Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware) SciClone Pharmaceuticals, Inc., a Delaware corporation (the “Company”), certifies as follows: 1. The Amended and Restated Certificate of Incorporation, as amended (the “Cert |
|
| February 21, 2017 |
Exhibit 4 Date: February 17, 2017 GL Capital Unit 3001, China World Tower 2 No. 1 Jian Guo Men Wai Avenue Beijing 100004, People’s Republic of China Attention: Shirley Lin Facsimile: +86-10-5961-1210 Bank of China Group Investment Limited 23rd Floor, 1 Garden Road, Central, Hong Kong Attention: Suet Mui Pang/Richard Zheng Facsimile: (852) 2810 9736 ABG Management Limited Unit 3002-3004, 30th Floor |
|
| February 21, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value US$0.001 per share (Title of Class of Securities) 8086 |
|
| February 17, 2017 |
SC 13D/A 1 d345805dsc13da.htm SCHEDULE 13D AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value US$0.001 per share (Title of Class of Securities) 80862K104 (CUSIP Number) Fan Yu Ally Bridge LB Management Limited Unit 30 |
|
| February 17, 2017 |
EX-99.7.04 2 d345805dex99704.htm EX-99.7.04 Exhibit 7.04 ABG Management Limited Unit 3002-3004, 30th Floor, Gloucester Tower The Landmark 15 Queen’s Road Central Hong Kong February 17, 2017 VIA FACSIMILE GL Capital Unit 3001, China World Tower 2 No. 1 Jian Guo Men Wai Avenue Beijing 100004, People’s Republic of China Attention: Shirley Lin Facsimile: +86-10-5961-1210 Jade Park C203, Lufthansa Offi |
|
| February 17, 2017 |
SC 13D/A 1 v459814sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value US$0.001 per sha |
|
| February 13, 2017 |
SciClone Pharmaceuticals 3G (Passive Acquisition of More Than 5% of Shares) SC 13G 1 sciclonepharmaceuticalsinc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: SciClone Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 80862K104 Date of Event Which Requires Filing of this Statement: December 31, 2016 Check the appropriate box to designate th |
|
| February 9, 2017 |
SCLN / SciClone Pharmaceuticals, Inc. / Man Group plc - MAN GROUP PLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* SciClone Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 80862K104 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| February 9, 2017 |
SC 13G 1 dfs454.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SCICLONE PHARMACEUTICALS INC (Name of Issuer) Common Stock (Title of Class of Securities) 80862K104 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| January 6, 2017 |
8-K 1 scln-20170106x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: January 4, 2017 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of i |
|
| November 15, 2016 |
SC 13D/A 1 ss19351sc13da.htm AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par |
|
| November 15, 2016 |
EX-99.3 2 ss19351ex9903.htm PROPOSAL Exhibit 3 November 14, 2016 The Board of Directors SciClone Pharmaceuticals, Inc. 950 Tower Lane Suite 900 Foster City, CA 94404, United States Dear Members of the Board of Directors: GL Capital Management GP Limited and its affiliates (“GL Capital”) and ABG Management Limited and its affiliates (“ABG”), on behalf of the consortium (the “Consortium”) formed to |
|
| November 14, 2016 |
EX-99.3 2 v452976ex99-3.htm EXHIBIT 3 Exhibit 3 November 14, 2016 The Board of Directors SciClone Pharmaceuticals, Inc. 950 Tower Lane Suite 900 Foster City, CA 94404, United States Dear Members of the Board of Directors: GL Capital Management GP Limited and its affiliates (“GL Capital”) and ABG Management Limited and its affiliates (“ABG”), on behalf of the consortium (the “Consortium”) formed to |
|
| November 14, 2016 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value US$0.001 per share (Title of Class of Securities) 80862K104 (CUSIP Number) Fan Yu Ally Bridge LB Management Limited Unit 3002-3004, 30th Floor Gloucester Tower, The Landmark |
|
| November 14, 2016 |
SC 13D/A 1 v452976sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value US$0.001 per sha |
|
| November 14, 2016 |
EX-99.7.03 Exhibit 7.03 November 14, 2016 The Board of Directors SciClone Pharmaceuticals, Inc. 950 Tower Lane Suite 900 Foster City, CA 94404, United States Dear Members of the Board of Directors: GL Capital Management GP Limited and its affiliates (“GL Capital”) and ABG Management Limited and its affiliates (“ABG”), on behalf of the consortium (the “Consortium”) formed to participate in the prev |
|
| November 9, 2016 |
SciClone Pharmaceuticals 10-Q (Quarterly Report) 2016093010Q Q3 Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 9, 2016 |
Exhibit 991 Q316 Financial Results Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS Company Revises Upward 2016 Non-GAAP Earnings Guidance, Confirms Revenue Guidance FOSTER CITY, CA – November 9, 2016 – SciClone P |
|
| November 9, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: November 9, 2016 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-19825 (Commiss |
|
| October 25, 2016 |
8-K 1 scln-20161024x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: October 24, 2016 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of |
|
| September 22, 2016 |
SCLN / SciClone Pharmaceuticals, Inc. / Man Group plc Passive Investment SC 13G 1 p16-1859sc13g.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* SciClone Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 80862K104 (CUSIP Number) September 16, 2016 (Date of Event Which Requires Filing of This Statement) Check the appropriate b |
|
| September 19, 2016 |
SNGX / Soligenix, Inc. / SCICLONE PHARMACEUTICALS INC - SC 13G Passive Investment SC 13G 1 d242954dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Soligenix, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834223208 (CUSIP Number) 9 September 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| September 9, 2016 |
SciClone Pharmaceuticals 3G/A (Passive Acquisition of More Than 5% of Shares) SC 13G/A 1 scic16a5.htm CUSIP NO. 80862K104 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 80862K104 (CUSIP Number) August 31, 2016 (Date of Event Which Requires Filing of th |
|
| August 9, 2016 |
SciClone Pharmaceuticals 10-Q (Quarterly Report) 2016063010Q Q2 Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 9, 2016 |
Exhibit 99.1 Q216 Financial Results Exhibit 99.1 ? Corporate Contacts ? ? Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] ? SCICLONE REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS ? ZADAXIN? Leads Continued Growth of Core Business in 2016 ? ? FOSTER CITY, CA ? August 9, 2016 ? SciClone Pharmaceuticals, Inc. (NAS |
|
| August 9, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 scln-20160809x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 9, 2016 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of in |
|
| August 9, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 scln-20160809x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 9, 2016 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of in |
|
| August 9, 2016 |
Exhibit 99.1 Q216 Financial Results Exhibit 99.1 ? Corporate Contacts ? ? Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] ? SCICLONE REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS ? ZADAXIN? Leads Continued Growth of Core Business in 2016 ? ? FOSTER CITY, CA ? August 9, 2016 ? SciClone Pharmaceuticals, Inc. (NAS |
|
| August 9, 2016 |
Form S-8 2016 Employee Stock Purchase Plan As filed with the Securities and Exchange Commission on August 9, 2016 ? Registration No. |
|
| August 9, 2016 |
AMENDMENT NO. 4 MANUFACTURING SERVICES AGREEMENT Exhibit 10.5 CONFIDENTIAL TREATMENT REQUEST – EDITED COPY *** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 4 TO MANUFACTURING SERVICES AGREEMENT THIS AMENDMENT NO. 4 TO MANUFACTU |
|
| August 9, 2016 |
Exhibit 10.3 CONFIDENTIAL TREATMENT REQUEST – EDITED COPY *** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 2 TO the Manufacturing Services Agreement (the “Agreement”) effec |
|
| August 9, 2016 |
AMENDMENT NO. 3 TO MANUFACTURING SERVICES AGREEMENT Exhibit 10.4 CONFIDENTIAL TREATMENT REQUEST – EDITED COPY *** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 3 TO MANUFACTURING SERVICES AGREEMENT THIS AMENDMENT NO. 3 TO MANUFACTURING |
|
| August 9, 2016 |
Manufacturing Services Agreement (the “Agreement”) Exhibit 10.1 CONFIDENTIAL TREATMENT REQUEST – EDITED COPY *** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Manufacturing Services Agreement (the “Agreement”) by and between Lonza Sales Ltd Münch |
|
| August 9, 2016 |
AMENDMENT NO. 1 TO MANUFACTURING SERVICES AGREEMENT Exhibit 10.2 CONFIDENTIAL TREATMENT REQUEST – EDITED COPY *** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 1 TO MANUFACTURING SERVICES AGREEMENT THIS AMENDMENT NO. 1 TO MANUFACTURING |
|
| August 3, 2016 |
Exhibit 991 Charles Meng Resignation Letter Exhibit 99.1 ? ? ? ? August 1, 2016 ? ? Mr. Charles Meng ? ? Dear Charles, ? The purpose of this letter is to summarize the agreement we have reached in our recent discussions and correspondence, regarding your resignation for personal reasons. ? ? 1. You will resign your officer or director positions with the Company and any subsidiary effective as of A |
|
| August 3, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 scln-20160803x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 1, 2016 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of in |
|
| June 15, 2016 |
8-K 1 scln-20160615x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: June 9, 2016 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of in |
|
| June 15, 2016 |
SCICLONE PHARMACEUTICALS, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN Exhibit 10.1 Exhibit 10.1 ? ? ? ? ? ? ? ? ? ? ? ? ? SCICLONE PHARMACEUTICALS, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN ? ? ? ? ? ? ? ? ? ? ? Table of Contents ? ? ? Page 1 Establishment, Purpose and Term of Plan 1 ? 1.1 Establishment 1 ? 1.2 Purpose 1 ? 1.3 Term of Plan 1 2 Definitions and Construction 1 ? 2.1 Definitions 1 ? 2.2 Construction 6 3 Administration 6 ? 3.1 Administration by the Committe |
|
| May 10, 2016 |
SciClone Pharmaceuticals 10-Q (Quarterly Report) 10-Q 1 scln-20160331x10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the |
|
| May 10, 2016 |
SciClone Pharmaceuticals 8-K (Current Report/Significant Event) 2016 Q116 Form 8-K Financial Results UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 10, 2016 |
Exhibit 991 Q116 Financial Results Exhibit 99.1 ? Corporate Contacts ? ? Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] ? SCICLONE REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS ? ZADAXIN? Leads Continued Growth of Core Business in 2016 ? ? FOSTER CITY, CA ? May 10, 2016 ? SciClone Pharmaceuticals, Inc. (NASDAQ: |
|
| May 9, 2016 |
SCLN / SciClone Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment SC 13G/A 1 scic16a4.htm CUSIP NO. 80862K104 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 80862K104 (CUSIP Number) April 30, 2016 (Date of Event Which Requires Filing of thi |
|
| April 29, 2016 |
SciClone Pharmaceuticals DEFA14A DEFA14A 1 v437727defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 29, 2016 |
SciClone Pharmaceuticals DEF 14A DEF 14A 1 c437622def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| March 11, 2016 |
SciClone Pharmaceuticals 10-K (Annual Report) 20151231 10K FY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 0-19825 SciClone P |
|
| March 11, 2016 |
EXHIBIT 10.42 CONFIDENTIAL TREATMENT REQUEST – EDITED COPY *** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. IMPORT AND DISTRIBUTION AGREEMENT SciClone Pharmaceuticals International China Holding L |
|
| March 11, 2016 |
EXHIBIT 10.41 CONFIDENTIAL TREATMENT REQUEST – EDITED COPY *** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL November 10, 2015 Sinopharm Holding Hong Kong International Limited 27/F 01 |
|
| March 11, 2016 |
EXHIBIT 10.40 CONFIDENTIAL TREATMENT REQUEST – EDITED COPY *** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL November 12, 2015 Sinopharm Holding Lingyun Biopharmaceutical (Shanghai) Co |
|
| March 11, 2016 |
EXHIBIT 21.1 SUBSIDIARIES OF REGISTRANT NOVAMED PHARMACEUTICALS INC. NOVAMED PHARMACEUTICALS (SHANGHAI) CO. LTD. SCICLONE PHARMACEUTICALS (CHINA) CO. LTD. SCICLONE PHARMACEUTICALS (CHINA) LTD SCICLONE PHARMACEUTICALS (HONG KONG) DEVELOPMENT COMPANY LTD. SCICLONE PHARMACEUTICALS HONG KONG LIMITED SCICLONE PHARMACEUTICALS INTERNATIONAL (CAYMAN) DEVELOPMENT LIMITED SCICLONE PHARMACEUTICALS INTERNATIO |
|
| March 10, 2016 |
Exhibit 991 Q415 Financial Results Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE REPORTS 2015 FINANCIAL RESULTS Results Achieve Revenue and Exceed EPS Expectations; SEC and DOJ Investigations Fully Resolved; Company Undertaking Strategic Review to Maximize Shareholder V |
|
| March 10, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 scln-20160310x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: March 10, 2016 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpora |
|
| February 22, 2016 |
EX-99.7.1 2 d140879dex9971.htm EX-99.7.1 Exhibit 7.01 JOINT FILING AGREEMENT THIS JOINT FILING AGREEMENT is entered into as of February 22, 2016, by and among the parties hereto. The undersigned hereby agree that the Statement on Schedule 13D with respect to the common stock, par value $0.001 per share, of SciClone Pharmaceuticals, Inc. and any amendment thereto signed by each of the undersigned s |
|
| February 22, 2016 |
EX-99.2 3 ss1406157ex9902.htm CONSORTIUM AGREEMENT Exhibit 2 Execution Version CONSORTIUM AGREEMENT GL Capital Management GP Limited Jade Park Investments Limited Bank of China Group Investment Limited and ABG Management Limited Dated as of February 22, 2016 TABLE OF CONTENTS Page ARTICLE I PARTICIPATION IN PROCESS; ADVISORS 1 Section 1.01 Participation in the Process and the Transaction 1 Section |
|
| February 22, 2016 |
SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value US$0.001 per share (Title of Class of Securities) 80862K104 (CUSIP Number) Fan Yu Ally Bridge LB Management Limited Unit 3002-3004, 30th Floor Gloucester Tower, The Landmark 15 Queen’s Road Cen |
|
| February 22, 2016 |
EX-99.7.2 3 d140879dex9972.htm EX-99.7.2 Exhibit 7.02 Execution Version CONSORTIUM AGREEMENT GL Capital Management GP Limited Jade Park Investments Limited Bank of China Group Investment Limited and ABG Management Limited Dated as of February 22, 2016 TABLE OF CONTENTS Page ARTICLE I PARTICIPATION IN PROCESS; ADVISORS 1 Section 1.01 Participation in the Process and the Transaction 1 Section 1.02 I |
|
| February 22, 2016 |
EX-99.1 2 ss1406157ex9901.htm JOINT FILING AGREEMENT Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including |
|
| February 22, 2016 |
SciClone Pharmaceuticals SCHEDULE 13D (Activist Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value US$0.001 per share (Title of Class of Securities) 80862 |
|
| February 22, 2016 |
EX-99.2 2 v432276ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 CONSORTIUM AGREEMENT GL Capital Management GP Limited Jade Park Investments Limited Bank of China Group Investment Limited and ABG Management Limited Dated as of February 22, 2016 TABLE OF CONTENTS Page Article I PARTICIPATION IN Process; ADVISORS 1 Section 1.01 Participation in the Process and the Transaction 1 Section 1.02 Information Sharing |
|
| February 22, 2016 |
SC 13D/A 1 v432276sc13da.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value US$0.001 p |
|
| February 10, 2016 |
SCLN / SciClone Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment scic15a3.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 80862K104 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 80862K104 (CUSIP Number) December 31, 2015 (Date o |
|
| February 9, 2016 |
SC 13G 1 rrd471.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SCICLONE PHARMACEUTICALS INC (Name of Issuer) Common Stock (Title of Class of Securities) 80862K104 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 9, 2016 |
SC 13D/A 1 v430606sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value US$0.001 per sha |
|
| February 4, 2016 |
Exhibit 991 Final Settlement with the SEC Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE ANNOUNCES FINAL RESOLUTION WITH THE SECURITIES AND EXCHANGE COMMISSION AND THE DEPARTMENT OF JUSTICE Company Undertaking a Full Strategic Review to Maximize Stockholder Value FOSTER |
|
| February 4, 2016 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 4, 2016 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-19825 (Commission Fil |
|
| January 11, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 scln-20160111x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: January 11, 2016 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpo |
|
| January 11, 2016 |
SciClone ANNOUNCES PRELIMINARY 2015 REVENUE Company Achieves Revenue Expectations For 2015 EX-99.1 2 scln-20160111ex99105f6ea.htm EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SciClone ANNOUNCES PRELIMINARY 2015 REVENUE Company Achieves Revenue Expectations For 2015 Foster City, Calif. – January 11, 2016 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today an |
|
| November 17, 2015 |
Entry into a Material Definitive Agreement 8-K 1 scln-20151117x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: November 12, 2015 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorp |
|
| November 9, 2015 |
Exhibit 991 Q315 Financial Results Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS Overall Performance Continues to Outpace China Pharmaceuticals Market Growth Rate; Non-GAAP EPS Guidance for 2015 Revised Upward FOSTER CITY, CA |
|
| November 9, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 scln-20151109x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: November 9, 2015 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpo |
|
| August 21, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value US$0.001 per share (Title of Class of Securities) 8086 |
|
| August 17, 2015 |
SC 13D/A 1 v418402sc13da.htm FORM SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value US$0.001 pe |
|
| August 10, 2015 |
EX-99.1 2 scln-20150810ex991f26ec1.htm EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS Company Reaches Agreement in Principle with SEC for Proposed Settlement; Reaffirms Revenue and EPS Guidance for 2015 FOSTER CITY, C |
|
| August 10, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 scln-20150810x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 10, 2015 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpor |
|
| July 8, 2015 |
S-8 1 scln-20150708xs8.htm S-8 As filed with the Securities and Exchange Commission on July 8, 2015 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 SCICLONE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 94-3116852 (State or other jurisdiction (IRS Employer of inc |
|
| June 17, 2015 |
SCICLONE PHARMACEUTICALS, INC. EMPLOYEE RETENTION AGREEMENT EX-10.2 3 d943764dex102.htm EX-10.2 Exhibit 10.2 SCICLONE PHARMACEUTICALS, INC. EMPLOYEE RETENTION AGREEMENT This EMPLOYEE RETENTION AGREEMENT (the “Agreement”) is effective as of [●], by and between [EMPLOYEE NAME] (“Employee”) and SciClone Pharmaceuticals, Inc., a Delaware corporation (the “Company”). For all purposes under this Agreement, the term “Company” shall include any successor to the Co |
|
| June 17, 2015 |
8-K 1 d943764d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: June 11, 2015 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdic |
|
| June 17, 2015 |
EX-10.1 2 d943764dex101.htm EX-10.1 Exhibit 10.1 SCICLONE PHARMACEUTICALS, INC. 2015 EQUITY INCENTIVE PLAN TABLE OF CONTENTS Page 1. Establishment, Purpose and Term of Plan 1 1.1 Establishment 1 1.2 Purpose 1 1.3 Term of Plan 1 2. Definitions and Construction 1 2.1 Definitions 1 2.2 Construction 8 3. Administration 9 3.1 Administration by the Committee 9 3.2 Authority of Officers 9 3.3 Administrat |
|
| May 27, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 scln-20150527x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 27, 2015 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporati |
|
| May 27, 2015 |
EX-99.1 2 scln-20150527ex991f7600c.htm EX-99.1 Exhibit 99.1 SciClone Pharmaceuticals, Inc. Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] Theravance Biopharma, Inc. Renee Gala Tim Brons Chief Financial Officer Vida Strategic Partners 650.808.4045 646.319.8981 [email protected] [email protected] |
|
| May 11, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 scln-20150511x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 11, 2015 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporati |
|
| May 11, 2015 |
EX-99.1 2 scln-20150511ex991d8a129.htm EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS ZADAXIN® Leads Continued Growth of Core Business in 2015 FOSTER CITY, CA – May 11, 2015 – SciClone Pharmaceuticals, Inc. (NASDAQ: SC |
|
| April 30, 2015 |
SciClone Pharmaceuticals DEF 14A DEF 14A 1 b407654def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 30, 2015 |
SciClone Pharmaceuticals DEFA14A DEFA14A 1 v408329defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 6, 2015 |
SciClone Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: March 31, 2015 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdiction of incorporatio |
|
| March 11, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 scln-20150311x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: March 11, 2015 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpora |
|
| March 11, 2015 |
Exhibit 99.1 2014 Financial Results and 2015 Outlook Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE REPORTS 2014 FINANCIAL RESULTS AND 2015 OUTLOOK Board of Directors Approves Additional $15 Million for Share Repurchase in 2015 FOSTER CITY, CA ? March 11, 2015 ? SciClone |
|
| February 6, 2015 |
SCLN / SciClone Pharmaceuticals, Inc. / STONEPINE CAPITAL, L.P. Passive Investment SC 13G/A 1 sciclone13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SciClone Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 80862K104 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 5, 2015 |
SCLN / SciClone Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment SC 13G/A 1 scic14a2.htm CUSIP NO. 80862K104 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SciClone Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 80862K104 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of |
|
| January 6, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 scln-20150106x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: January 6, 2015 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpor |
|
| January 6, 2015 |
SciClone PROVIDES 2014 FINANCIAL UPDATE AND 2015 REVENUE EX-99.1 2 scln-20150106ex9918d2b19.htm EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SciClone PROVIDES 2014 FINANCIAL UPDATE AND 2015 REVENUE GUIDANCE Foster City, Calif. – January 6, 2015 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reconfirmed its anticipated |
|
| December 18, 2014 |
EX-99.1 2 scln-20141218ex991cf40ca.htm EX-99.1 Exhibit 99.1 Corporate Contacts The Medicines Company SciClone Pharmaceuticals Media: Media/Investors Bob Laverty, +1 973 290 6162 Jane Green, + 1 650 358 1447 Mobile: +1 609 558 5570 [email protected] Vice President, Communications Office of D.E.S.I.G.N. [email protected] or Investors: Neera Dahiya Ravindran, MD +1 973 290 6044 Vice Presi |
|
| December 18, 2014 |
Financial Statements and Exhibits, Other Events 8-K 1 scln-20141218x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: December 18, 2014 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorp |
|
| November 10, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: November 10, 2014 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-19825 (Commission Fi |
|
| November 10, 2014 |
Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER 2014 2014 EPS Guidance Revised Upward; ZADAXIN® Leads Continued Growth of Core Business in 2014 FOSTER CITY, CA – November 10, 2014 – SciClone Pharmaceuticals, Inc. (NASDAQ: SC |
|
| August 28, 2014 |
SciClone and BTG ANNOUNCE THAT DC BEAD® HAS BEEN APPROVED BY CHINA FOOD AND DRUG ADMINISTRATION EX-99.1 2 scln-20140828ex9916bf999.htm EX-99.1 Exhibit 99.1 SciClone and BTG ANNOUNCE THAT DC BEAD® HAS BEEN APPROVED BY CHINA FOOD AND DRUG ADMINISTRATION Foster City, Calif. – August 28, 2014 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), and its partner BTG plc (LSE: BTG), today announced that the China Food and Drug Administration has approved the registration of DC Bead® for the embolizatio |
|
| August 28, 2014 |
Financial Statements and Exhibits, Other Events 8-K 1 scln-20140828x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 28, 2014 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpor |
|
| August 11, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d774672d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 11, 2014 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisd |
|
| August 11, 2014 |
EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER 2014 2014 EPS Guidance Revised Upward Board of Directors Authorizes Additional Stock Repurchase of Up To $15 Million FOSTER CITY, CA – August 11, 2014 – SciClone Pharm |
|
| June 13, 2014 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: June 12, 2014 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdiction of incorporation |
|
| June 5, 2014 |
- DEFINITIVE ADDITIONAL MATERIALS DEFA14A 1 d739408ddefa14a.htm DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of |
|
| May 12, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d724159d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 12, 2014 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdict |
|
| May 12, 2014 |
EX-99.1 2 d724159dex991.htm EX-99.1 EXHIBIT 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER 2014 ZADAXIN® Revenues Up 30% Compared to First Quarter 2013 FOSTER CITY, CA — May 12, 2014 — SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) |
|
| April 30, 2014 |
Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 4, 2014 |
SCLN / SciClone Pharmaceuticals, Inc. / STONEPINE CAPITAL, L.P. - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| April 4, 2014 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to certain shares of common stock of SciClone Pharmaceuticals, Inc. and further agree that this Joint Filing Agreement shall be |
|
| March 17, 2014 |
SciClone Pharmaceuticals FORM 10-K (Annual Report) 10-K 1 d657541d10k.htm FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commis |
|
| March 12, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d691639d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: March 12, 2014 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdiction |
|
| March 12, 2014 |
SCICLONE REPORTS 2013 FINANCIAL RESULTS AND 2014 OUTLOOK EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE REPORTS 2013 FINANCIAL RESULTS AND 2014 OUTLOOK FOSTER CITY, CA – March 12, 2014 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the fourth quarter and year ended December 31, 201 |
|
| February 11, 2014 |
SCLN / SciClone Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment scic13a1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 80862K104 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SciClone Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 80862K104 (CUSIP Number) December 31, 2013 (Date o |
|
| January 24, 2014 |
EX-16 Exhibit 16 January 24, 2014 Securities and Exchange Commission 100 F Street, N. |
|
| January 24, 2014 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 17, 2014 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdiction of incorporati |
|
| January 16, 2014 |
8-K 1 d657579d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: January 16, 2014 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other juris |
|
| January 16, 2014 |
AMENDED AND RESTATED BYLAWS SCICLONE PHARMACEUTICALS, INC. ARTICLE I EX-3.II 2 d657579dex3ii.htm EX-3.II Exhibit 3(ii) AMENDED AND RESTATED BYLAWS OF SCICLONE PHARMACEUTICALS, INC. ARTICLE I STOCKHOLDERS SECTION 1.1 Place of Meetings. All meetings of stockholders shall be held at such place within or without the State of Delaware as may be designated from time to time by the Board of Directors of the corporation (the “Board” or the “Board of Directors”) or the Pres |
|
| January 9, 2014 |
EX-99.1 2 d655796dex991.htm EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE PROVIDES 2013 FINANCIAL UPDATE AND 2014 GUIDANCE Foster City, Calif. – January 9, 2014 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced its anticipated year-end 2013 cash po |
|
| January 9, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d655796d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: January 9, 2014 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisd |
|
| January 2, 2014 |
EX-10.1 2 d649536dex101.htm EX-10.1 Exhibit 10.1 SECOND AMENDMENT THIS SECOND AMENDMENT (this “Amendment”) is made and entered into as of December 20, 2013, by and between CA-METRO CENTER LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”), and SCICLONE PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain lease dated May |
|
| January 2, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d649536d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: December 31, 2013 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other juri |
|
| November 21, 2013 |
SC 13D/A 1 v360994sc13da.htm FORM SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) SCICLONE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value US$0.001 pe |
|
| November 14, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K/A 1 d629293d8ka.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: November 12, 2013 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other ju |
|
| November 14, 2013 |
EX-99.1 2 d629293dex991.htm EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE REPORTS FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2013 FOSTER CITY, CA – November 12, 2013 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financia |
|
| November 14, 2013 |
EX-99.2 3 d629293dex992.htm EX-99.2 Exhibit 99.2 1 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us © 2013 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. ‘Thomson Reuters’ and the Thomson Reuters logo are registered trademarks |
|
| November 12, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d627557d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: November 12, 2013 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other juri |
|
| November 12, 2013 |
EX-99.1 2 d627557dex991.htm EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE REPORTS FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2013 FOSTER CITY, CA – November 12, 2013 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financia |
|
| October 7, 2013 |
Correspondence October 7, 2013 Mr. Jim B. Rosenberg Senior Assistant Chief Accountant United States Securities and Exchange Commission Washington, D.C. 20549 Re: SciClone Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2012 Filed April 1, 2013 File No. 000-19825 Dear Mr. Rosenberg: This letter responds to the letter of the staff (the “Staff”) of the Securities and Exchange C |
|
| September 23, 2013 |
EX-99.1 2 d598849dex991.htm EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE APPOINTS NANCY T. CHANG, PH.D., TO ITS BOARD OF DIRECTORS Foster City, Calif. – September 23, 2013 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Nancy T. Chang, Ph.D |
|
| September 23, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: September 17, 2013 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdiction of incorpor |
|
| August 30, 2013 |
Correspondence August 30, 2013 Mr. Joel Parker Accounting Branch Chief United States Securities and Exchange Commission Washington, D.C. 20549 Re: SciClone Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2012 Filed April 1, 2013 File No. 000-19825 Dear Mr. Parker: This letter responds to the letter of the staff (the “Staff”) of the Securities and Exchange Commission (the “SE |
|
| August 21, 2013 |
CORRESP 1 filename1.htm August 21, 2013 VIA EDGAR Lisa Vanjoske Assistant Chief Accountant Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: SciClone Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2012 Filed April 1, 2013 File No. 000-19825 Dear Ms. Vanjoske: This letter is submitted on behalf of SciClone Pharmaceut |
|
| August 7, 2013 |
EX-99.1 2 d581324dex991.htm EX-99.1 Exhibit 99.1 Corporate Contacts Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected] SCICLONE REPORTS FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2013 AND UPDATES 2013 GUIDANCE FOSTER CITY, CA – August 7, 2013 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today |
|
| August 7, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d581324d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 7, 2013 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdic |
|
| July 17, 2013 |
CORRESP 1 filename1.htm July 17, 2013 Mr. Jim B. Rosenberg Senior Assistant Chief Accountant United States Securities and Exchange Commission Washington, D.C. 20549 Re: SciClone Pharmaceuticals, Inc. File No. 000-19825 Form 10-K for the Fiscal Year Ended December 31, 2012 Form 10-Q for the Quarterly Period Ended September 30, 2012 Dear Mr. Rosenberg: This letter responds to the letter of the staff |
|
| July 15, 2013 |
8-K 1 d567575d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: July 15, 2013 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdic |
|
| July 15, 2013 |
SCICLONE APPOINTS WILSON W. CHEUNG AS CHIEF FINANCIAL OFFICER EX-99.1 2 d567575dex991.htm EX-99.1 Exhibit 99.1 Corporate Contacts Jane Green Investors/Media 650.358.1447 [email protected] SCICLONE APPOINTS WILSON W. CHEUNG AS CHIEF FINANCIAL OFFICER Foster City, Calif. – July 15, 2013 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment of Wilson W. Cheung as Chief Financial Officer and Senior Vice President, Finance. Mr. Cheung |
|
| June 28, 2013 |
8-K 1 d560913d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: June 24, 2013 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdic |
|
| June 28, 2013 |
EX-99.1 2 d560913dex991.htm EX-99.1 Exhibit 99.1 Corporate Contacts Jane Green Paggy Liou SciClone Investors/Media Taiwan Liposome Company/Media 650.358.1447 886 (2) 2655.7377 ext.105 [email protected] [email protected] SCICLONE AND TAIWAN LIPOSOME COMPANY ENTER INTO A LICENSING AGREEMENT FOR PROFLOW®, A NOVEL TREATMENT FOR PERIPHERAL ARTERIAL DISEASE FOR THE CHINA MARKET Foster City, Calif. and |
|
| June 19, 2013 |
CORRESP 1 filename1.htm June 19, 2013 VIA EDGAR Jim B. Rosenberg Senior Assistant Chief Accountant Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: SciClone Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2012 Filed April 1, 2013 Form 10-Q for the Quarterly Period Ended September 30, 2012 Filed November 9, 2012 File |
|
| May 31, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 31, 2013 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdiction of incorporation) (Commiss |
|
| May 23, 2013 |
DEF 14A 1 d503608ddef14a.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Co |
|
| May 16, 2013 |
8-K 1 d540390d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 13, 2013 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdict |
|
| May 16, 2013 |
SCICLONE REPORTS ANTICIPATED FINANCIAL RESULTS FOR THE FIRST QUARTER 2013 EX-99.2 3 d540390dex992.htm EX-99.2 Exhibit 99.2 Corporate Contacts Gary Titus Jane Green Chief Financial Officer Investors/Media 650.358.3456 650.358.1447 [email protected] [email protected] SCICLONE REPORTS ANTICIPATED FINANCIAL RESULTS FOR THE FIRST QUARTER 2013 FOSTER CITY, CA – May 16, 2013 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported its expectations regarding financial |
|
| May 16, 2013 |
EX-99.1 2 d540390dex991.htm EX-99.1 Exhibit 99.1 Corporate Contacts Gary Titus Jane Green Chief Financial Officer Investors/Media 650.358.3456 650.358.1447 [email protected] [email protected] SCICLONE AND ZENSUN ENTER INTO A LICENSING AGREEMENT FOR NOVEL CHRONIC HEART FAILURE DRUG NEUCARDIN™ FOR THE CHINA MARKET Foster City, Calif. – May 16, 2013 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) |
|
| May 13, 2013 |
NT 10-Q 1 d517060dnt10q.htm NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-19825 CUSIP Number: 80862K104 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2013 ¨ Transition Report on Form 10-K ¨ Transition Rep |
|
| April 8, 2013 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K 1 d517817d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 8, 2013 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdict |
|
| April 8, 2013 |
SCICLONE APPOINTS PRICEWATERHOUSECOOPERS LLP AS ITS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-99.1 2 d517817dex991.htm EX-99.1 Exhibit 99.1 Corporate Contacts Gary Titus Jane Green Chief Financial Officer Investors/Media 650.358.3456 650.358.1447 [email protected] [email protected] SCICLONE APPOINTS PRICEWATERHOUSECOOPERS LLP AS ITS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Foster City, Calif. – April 8, 2013 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the Au |
|
| April 5, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d517597d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 1, 2013 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdict |
|
| April 5, 2013 |
EX-16 2 d517153dex16.htm EX-16 Exhibit 16 Securities and Exchange Commission April 5, 2013 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01(a) of Form 8-K/A dated April 5, 2013, of SciClone Pharmaceuticals, Inc. and are in agreement with the statements contained in the first, second, third and fourth paragraphs on page 2 therein. We have no basis to agree or dis |
|
| April 5, 2013 |
8-K/A 1 d517153d8ka.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 18, 2013 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116 |
|
| April 5, 2013 |
EX-99.1 2 d517597dex991.htm EX-99.1 Exhibit 99.1 Corporate Contacts Gary Titus Jane Green Chief Financial Officer Investors/Media 650.358.3456 650.358.1447 [email protected] [email protected] SCICLONE REPORTS 2012 FINANCIAL RESULTS AND 2013 OUTLOOK Company Completes Restatement of Prior Periods FOSTER CITY, CA – April 1, 2013 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported finan |
|
| April 5, 2013 |
EX-99.2 3 d517597dex992.htm EX-99.2 Exhibit 99.2 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT SCLN - Q4 2012 SciClone Pharmaceuticals, Inc. Earnings Conference Call EVENT DATE/TIME: APRIL 01, 2013 / 08:30PM GMT THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us © 2013 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by fram |
|
| March 22, 2013 |
8-K 1 d506206d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: March 22, 2013 (Date of earliest event reported) SciClone Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19825 94-3116852 (State or other jurisdi |
|
| March 22, 2013 |
EX-99.1 2 d506206dex991.htm EX-99.1 Exhibit 99.1 Corporate Contacts Gary Titus Jane Green Chief Financial Officer Investors/Media 650.358.3456 650.358.1447 [email protected] [email protected] SCICLONE APPOINTS HONG ZHAO AS CHIEF EXECUTIVE OFFICER, CHINA OPERATIONS Foster City, Calif. – March 22, 2013 – SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the appointment of Hong Zhao a |
